All In Biotech

Drug Trial Radar · NCT06867718

Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions

A Phase 2 Study of Once-Daily RGT001-075 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities (COMO-1)

Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 267 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

267

Actual

Start

Jan 24, 2025

Primary completion

Nov 6, 2025

Study completion Nov 6, 2025

Sponsor

Lead sponsor
Regor Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Mar 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, 36-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of RGT001-075 in adults who are obese (BMI ≥30 kg/m²) or who are overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. RGT001-075 or matching placebo will be administered once daily.

Conditions

  • Obesity or Overweight

Interventions

  • RGT001-075Drug

    RGT001-075 is a small molecule GLP-1 agonist

  • Placebo ComparatorDrug

    Placebo comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in body weight at Week 36Time frame: Baseline and 36 weeks

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Alliance for Multispecialty Research, LLC

    Mobile, Alabama

  • Synexus Clinical Research

    Phoenix, Arizona

  • Velocity Clinical Research

    Huntington Park, California

  • Angels Clinical Research

    Doral, Florida

  • Optimal Research

    Melbourne, Florida

  • Angels Clinical Research

    Miami, Florida

  • Palm Springs Community Health Center

    Miami Lakes, Florida

  • Synexus Clinical Research

    The Villages, Florida

  • Javara-Privia Medical Group, Georgia LLC

    Savannah, Georgia

  • Javara-Privia Medical Group, Georgia, LLC

    Thomasville, Georgia

  • Synexus Clinical Research

    Evansville, Indiana

  • Velocity Clinical Research

    Valparaiso, Indiana

  • Alliance for Multispecialty Research, LLC

    Lexington, Kentucky

  • Velocity Clinical Research

    Baton Rouge, Louisiana

  • Velocity Clinical Research

    Rockville, Maryland

  • Mankato Clinic-East Main Street-Javara

    Mankato, Minnesota

  • Synexus Clinical Research

    Richfield, Minnesota

  • Synexus Clinical Research

    Creve Coeur, Missouri

  • Velocity Clinical Research

    Omaha, Nebraska

  • Premier Health Research-Sparta-Objective Health

    Sparta, New Jersey

  • Velocity Clinical Research

    Vestal, New York

  • Javara-Tryon Medical Partners, PLLC

    Charlotte, North Carolina

  • Velocity Clinical Research

    Durham, North Carolina

  • Velocity Clinical Research

    Cincinnati, Ohio

  • Velocity Clinical Research

    Cleveland, Ohio

  • Alliance for Multispecialty Research, LLC

    Norman, Oklahoma

  • Velocity Clinical Research

    East Greenwich, Rhode Island

  • Velocity Clinical Research

    Dallas, Texas

  • Synexus Clinical Research

    Dallas, Texas

  • Synexus Clinical Research

    San Antonio, Texas

  • Javara-Privia Medical Group Gulf Coast PLLC

    The Woodlands, Texas

  • Velocity Clinical Research

    Waco, Texas

  • Synexus Clinical Research

    Salt Lake City, Utah

  • Velocity Clinical Research

    West Jordan, Utah

  • Velocity Clinical Research

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.